About PredictImmune
PredictImmune is a company based in Cambridge (United Kingdom) founded in 2017. PredictImmune has raised $18.32 million across 3 funding rounds from investors including University of Cambridge, Parkwalk and BGF. The company has 15 employees as of March 31, 2021. PredictImmune operates in a competitive market with competitors including ArcherDX, BioLife Solutions, Qiagen, Devyser and RoosterBio, among others.
- Headquarter Cambridge, United Kingdom
- Employees 15 as on 31 Mar, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Predictimmune Limited
- Date of Incorporation 13 Jan, 2017
- Jurisdiction LONDON, ENGLAND
-
Annual Revenue
$107.44 K (USD)22as on Mar 31, 2022
-
Net Profit
-$2.28 M (USD)38as on Mar 31, 2022
-
EBITDA
-$3.2 M (USD)27as on Mar 31, 2022
-
Total Equity Funding
$18.32 M (USD)
in 3 rounds
-
Latest Funding Round
$12.25 M (USD), Series B
Jul 30, 2019
-
Investors
University of Cambridge
& 5 more
-
Employee Count
15
as on Mar 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of PredictImmune
Unlock access to complete
Unlock access to complete
Funding Insights of PredictImmune
PredictImmune has successfully raised a total of $18.32M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $12.25 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in PredictImmune
PredictImmune has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include University of Cambridge, Parkwalk and BGF.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech companies are invested in by Parkwalk venture capital firm.
|
Locked | Locked | Locked | |
|
Early & Growth stage tech & offline focused VC firm funding companies in the UK & Ireland
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for PredictImmune
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PredictImmune
Investment portfolio details for PredictImmune
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - PredictImmune
Detailed financials for PredictImmune
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Predictimmune Comparisons
Peer comparison for PredictImmune
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PredictImmune
PredictImmune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ArcherDX, BioLife Solutions, Qiagen, Devyser and RoosterBio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Tissue hypothermic storage and cryopreservation freeze media are developed.
|
|
| Locked | Locked | Locked |
Products and reagents for molecular diagnostic assays are supplied.
|
|
| Locked | Locked | Locked |
Provider of molecular diagnostic kits for cancer, hereditary diseases, and reproductive disorders
|
|
| Locked | Locked | Locked |
Developer of human mesenchymal stem cells and extracellular vesicles
|
|
| Locked | Locked | Locked |
Developer of diagnostic instruments and reagents for autoimmune diseases and allergies
|
Detailed competitors of PredictImmune
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Predictimmune
Complete news archive for PredictImmune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PredictImmune
PredictImmune was founded in 2017.
PredictImmune is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
PredictImmune is a funded company, having raised a total of $18.32M across 3 funding rounds to date.
As of Mar 31, 2021, the latest employee count at PredictImmune is 15.
Annual revenue of PredictImmune is $107.44K as on Mar 31, 2022.
PredictImmune was founded in 2017 and is based in Cambridge, United Kingdom. Operations focus on the diagnostics sector within biotechnology, where prognostic tools are developed to support treatment decisions for immune-mediated inflammatory diseases. The initial product, PredictSURE IBD, is used to stratify patients with inflammatory bowel disease, including Crohns disease and ulcerative colitis, to inform clinical outcomes.
PredictImmune's top competitors include Qiagen, ArcherDX and RoosterBio.
PredictImmune has 6 investors. Key investors include University of Cambridge, Parkwalk, BGF, Cambridge Innovation Capital, and Wellcome.